Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among […]
